NASDAQ$SRRK
Scholar Rock Holding Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Scholar Rock reported full year financial results and highlighted business progress.
Scholar Rock reported a net loss of $86.5 million for the full year ended December 31, 2020. The company ended the year with approximately $341 million in cash, cash equivalents, and marketable securities.
- TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).
- SRK-181 DRAGON Phase 1 trial is enrolling patients with solid tumors in Part A.
- A new U.S. patent was issued providing protection for broad therapeutic use of apitegromab.
- The company ended 2020 with approximately $341 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Scholar Rock · Revenue · Quarterly
$3.44M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+3.6%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
58%
18 / 31 earnings
Positive
+24.6%
Q4 2023
Best reaction
-7.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | +4.4% | -6.1% | |
| Q4 2025 | +2.0% | +4.2% | +15.0% | |
| Q3 2025 | +24.1% | +32.0% | +55.9% | |
| Q2 2025 | -6.1% | -14.9% | -15.1% | |
| Q1 2025 | -2.6% | -3.9% | +3.3% | |
| Q4 2024 | -2.9% | +0.2% | -11.3% | |
| Q3 2024 | -2.7% | -5.9% | +48.0% | |
| Q1 2024 | -3.7% | -11.4% | -37.4% | |
| Q4 2023 | +24.6% | +24.2% | +5.7% | |
| Q3 2023 | -1.8% | -17.5% | +44.2% | |
| Q2 2023 | +6.3% | +11.6% | -3.6% | |
| Q1 2023 | +4.4% | -0.1% | -13.6% | |
| Q4 2022 | +7.2% | -1.9% | -15.7% | |
| Q3 2022 | +10.9% | +0.2% | +1.5% | |
| Q2 2022 | +6.9% | +32.9% | +5.2% | |
| Q1 2022 | +7.3% | -5.2% | -9.7% | |
| Q4 2021 | -5.1% | -9.5% | -8.6% | |
| Q3 2021 | +16.8% | +24.2% | -10.4% | |
| Q2 2021 | +4.8% | +7.5% | +4.6% | |
| Q1 2021 | -2.4% | +0.1% | +10.6% | |
| Q4 2020 | +16.8% | +21.4% | -40.2% | |
| Q3 2020 | -1.0% | +2.8% | +7.7% | |
| Q2 2020 | +3.9% | -4.1% | +5.0% | |
| Q1 2020 | -4.8% | +6.9% | +2.2% | |
| Q4 2019 | +4.3% | +9.4% | -1.1% | |
| Q3 2019 | -7.6% | -14.5% | +17.0% | |
| Q2 2019 | +0.8% | +11.9% | +19.4% | |
| Q1 2019 | +6.2% | +8.6% | -4.9% | |
| Q4 2018 | +9.8% | +2.3% | -7.4% | |
| Q3 2018 | +2.0% | -10.0% | -1.6% | |
| Q2 2018 | -6.7% | -11.9% | +51.0% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro